Gene

Search results

No.	KEGG GENES	KEGG PATHWAY	KEGG DRUG	DrugBank	Disease ID
1	SIGMAR1	[2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases	D00848	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
2	SIGMAR1	[2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases	D03742	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
3	SIGMAR1	[2] Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases	D03744	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
4	TUBB3	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00491	Paclitaxel	[2] 46, 85
5	TUBB3	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00570	Colchicine	[7] 2, 42, 46, 56, 93, 210, 266
6	TUBB3	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D05333	Paclitaxel	[2] 46, 85
7	TUBB4A	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00491	Paclitaxel	[2] 46, 85
8	TUBB4A	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00570	Colchicine	[7] 2, 42, 46, 56, 93, 210, 266
9	TUBB4A	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D05333	Paclitaxel	[2] 46, 85
10	TUBB4B	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00491	Paclitaxel	[2] 46, 85
11	TUBB4B	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00570	Colchicine	[7] 2, 42, 46, 56, 93, 210, 266
12	TUBB4B	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D05333	Paclitaxel	[2] 46, 85
13	CD52	-	D02802	Alemtuzumab	[15] 46, 49, 51, 60, 62, 63, 65, 85, 96, 164, 234, 283, 284, 285, 326
14	TNFSF13B	[4] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis	D03068	Belimumab	[12] 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300
15	TNFSF13B	[4] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis	D09704	Atacicept	[4] 13, 46, 49, 66
16	TNFSF13B	[4] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis	D10083	Tabalumab	[2] 46, 49
17	CYSLTR1	[2] Calcium signaling pathway, Neuroactive ligand-receptor interaction	D00529	Montelukast	[8] 6, 13, 46, 61, 63, 85, 98, 228
18	CYSLTR1	[2] Calcium signaling pathway, Neuroactive ligand-receptor interaction	D08229	Montelukast	[8] 6, 13, 46, 61, 63, 85, 98, 228
19	IL17F	[4] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease	D11550	Bimekizumab	[3] 46, 97, 271
20	TNFRSF13C	[5] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Human T-cell leukemia virus 1 infection, Primary immunodeficiency	D12151	Ianalumab	[5] 35, 46, 49, 53, 95
21	CCR5	[9] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Endocytosis, Toxoplasmosis, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis	D06670	Maraviroc	[2] 46, 84
22	CNR1	[4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling	D00306	Dronabinol	[8] 2, 8, 13, 36, 46, 96, 271, 298
23	CNR1	[4] Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling	D10915	Cannabidiol	[19] 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
24	CNR2	[1] Neuroactive ligand-receptor interaction	D00306	Dronabinol	[4] 46, 96, 271, 298
25	CNR2	[1] Neuroactive ligand-receptor interaction	D10915	Cannabidiol	[14] 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
26	ADORA1	[7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
27	ADORA1	[7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
28	ADORA1	[7] cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction	D02769	Adenosine phosphate	[1] 46
29	ADORA2A	[7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
30	ADORA2A	[7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
31	ADORA2A	[7] Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism	D02769	Adenosine phosphate	[1] 46
32	ADORA2B	[5] Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism	D02769	Adenosine phosphate	[1] 46
33	ADORA3	[3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction	D02769	Adenosine phosphate	[1] 46
34	ADORA3	[3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction	D10971	Piclidenoson	[1] 46
35	CSF2	[16] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Shigellosis, Amoebiasis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Coronavirus disease - COVID-19, Transcriptional misregulation in cancer, Acute myeloid leukemia, Rheumatoid arthritis	D11343	Otilimab	[2] 46, 256
36	CSF2RA	[4] Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer	D09930	Mavrilimumab	[2] 41, 46
37	CSF3R	[5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer	D03235	Filgrastim	[34] 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
38	ADRA1D	[6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion	D00095	Epinephrine	[3] 46, 70, 96
39	ADRA1D	[6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion	D00996	Epinephrine	[3] 46, 70, 96
40	ADRA1D	[6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion	D02149	Epinephrine	[3] 46, 70, 96
41	ADRA1B	[6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion	D00095	Epinephrine	[3] 46, 70, 96
42	ADRA1B	[6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion	D00996	Epinephrine	[3] 46, 70, 96
43	ADRA1B	[6] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion	D02149	Epinephrine	[3] 46, 70, 96
44	ADRA1A	[7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion	D00095	Epinephrine	[3] 46, 70, 96
45	ADRA1A	[7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion	D00996	Epinephrine	[3] 46, 70, 96
46	ADRA1A	[7] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion	D02149	Epinephrine	[3] 46, 70, 96
47	ADRA2A	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D00095	Epinephrine	[3] 46, 70, 96
48	ADRA2A	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D00514	Dexmedetomidine	[13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
49	ADRA2A	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D00996	Epinephrine	[3] 46, 70, 96
50	ADRA2A	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D01205	Dexmedetomidine	[13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
51	ADRA2A	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D02149	Epinephrine	[3] 46, 70, 96
52	ADRA2B	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D00095	Epinephrine	[3] 46, 70, 96
53	ADRA2B	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D00514	Dexmedetomidine	[13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
54	ADRA2B	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D00996	Epinephrine	[3] 46, 70, 96
55	ADRA2B	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D01205	Dexmedetomidine	[13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
56	ADRA2B	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D02149	Epinephrine	[3] 46, 70, 96
57	ADRA2C	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D00095	Epinephrine	[3] 46, 70, 96
58	ADRA2C	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D00514	Dexmedetomidine	[13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
59	ADRA2C	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D00996	Epinephrine	[3] 46, 70, 96
60	ADRA2C	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D01205	Dexmedetomidine	[13] 2, 4, 6, 21, 34, 46, 70, 107, 113, 212, 215, 226, 280
61	ADRA2C	[2] cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction	D02149	Epinephrine	[3] 46, 70, 96
62	ADRB1	[11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy	D00095	Epinephrine	[3] 46, 70, 96
63	ADRB1	[11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy	D00996	Epinephrine	[3] 46, 70, 96
64	ADRB1	[11] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Gap junction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy	D02149	Epinephrine	[3] 46, 70, 96
65	ADRB2	[9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation	D00095	Epinephrine	[3] 46, 70, 96
66	ADRB2	[9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation	D00996	Epinephrine	[3] 46, 70, 96
67	ADRB2	[9] Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation	D02149	Epinephrine	[3] 46, 70, 96
68	ADRB3	[8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation	D00095	Epinephrine	[3] 46, 70, 96
69	ADRB3	[8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation	D00996	Epinephrine	[3] 46, 70, 96
70	ADRB3	[8] Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation	D02149	Epinephrine	[3] 46, 70, 96
71	ACE	[6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy	D00251	Captopril	[8] 6, 17, 46, 86, 96, 97, 107, 271
72	ACE	[6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy	D00362	Lisinopril	[7] 19, 46, 49, 66, 67, 113, 222
73	ACE	[6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy	D00421	Ramipril	[7] 46, 49, 66, 67, 113, 218, 257
74	ACE	[6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy	D00621	Enalapril	[6] 19, 46, 66, 113, 210, 222
75	ACE	[6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy	D07892	Enalapril	[6] 19, 46, 66, 113, 210, 222
76	ACE	[6] Renin-angiotensin system, Renin secretion, Chagas disease, Coronavirus disease - COVID-19, Hypertrophic cardiomyopathy, Diabetic cardiomyopathy	D08131	Lisinopril	[7] 19, 46, 49, 66, 67, 113, 222
77	DHFR	[5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance	D00142	Methotrexate	[38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
78	DHFR	[5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance	D02115	Methotrexate	[38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
79	DHODH	[3] Pyrimidine metabolism, Metabolic pathways, Biosynthesis of cofactors	D00749	Leflunomide	[12] 11, 40, 46, 49, 53, 66, 107, 162, 224, 270, 271, 300
80	NQO1	[7] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis	D00564	Warfarin	[13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
81	NQO1	[7] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis	D01280	Warfarin	[13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
82	NQO1	[7] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis	D08682	Warfarin	[13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
83	DRD2	[8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism	D01226	Sulpiride	[5] 2, 6, 17, 46, 70
84	DRD2	[8] Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism	D08549	Sulpiride	[5] 2, 6, 17, 46, 70
85	AGTR1	[16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy	D00150	Angiotensin II	[7] 17, 19, 46, 66, 86, 222, 224
86	AGTR1	[16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy	D00357	Losartan	[18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
87	AGTR1	[16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy	D02014	Angiotensin II	[7] 17, 19, 46, 66, 86, 222, 224
88	AGTR1	[16] Calcium signaling pathway, cGMP-PKG signaling pathway, Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Apelin signaling pathway, Renin-angiotensin system, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, AGE-RAGE signaling pathway in diabetic complications, Cushing syndrome, Coronavirus disease - COVID-19, Pathways in cancer, Diabetic cardiomyopathy	D08146	Losartan	[18] 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299
89	AGTR2	[3] Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system	D00150	Angiotensin II	[7] 17, 19, 46, 66, 86, 222, 224
90	AGTR2	[3] Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Renin-angiotensin system	D02014	Angiotensin II	[7] 17, 19, 46, 66, 86, 222, 224
91	DHFR2	[5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance	D00142	Methotrexate	[38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
92	DHFR2	[5] One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance	D02115	Methotrexate	[38] 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
93	TUBB	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00491	Paclitaxel	[2] 46, 85
94	TUBB	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00570	Colchicine	[7] 2, 42, 46, 56, 93, 210, 266
95	TUBB	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D05333	Paclitaxel	[2] 46, 85
96	EPOR	[5] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer	D03231	Erythropoietin	[10] 2, 6, 13, 18, 22, 46, 47, 70, 95, 96
97	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D00105	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
98	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D00554	Ethinylestradiol	[4] 13, 46, 49, 299
99	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D00575	Mestranol	[2] 46, 49
100	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D01413	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
101	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D01617	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
102	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D01953	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
103	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D02217	Raloxifene	[1] 46
104	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D04061	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
105	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D04063	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
106	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D04064	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
107	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D04065	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
108	ESR1	[9] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D08465	Raloxifene	[1] 46
109	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D00105	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
110	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D00575	Mestranol	[2] 46, 49
111	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D01413	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
112	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D01617	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
113	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D01953	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
114	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D02217	Raloxifene	[1] 46
115	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D04061	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
116	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D04063	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
117	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D04064	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
118	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D04065	Estradiol	[7] 13, 46, 49, 65, 76, 226, 299
119	ESR2	[7] Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer	D08465	Raloxifene	[1] 46
120	F10	[1] Complement and coagulation cascades	D07086	Rivaroxaban	[5] 46, 49, 75, 91, 210
121	F10	[1] Complement and coagulation cascades	D09710	Edoxaban	[2] 46, 88
122	FCER1A	[4] Sphingolipid signaling pathway, Phospholipase D signaling pathway, Fc epsilon RI signaling pathway, Asthma	D05251	Omalizumab	[7] 46, 53, 65, 98, 162, 226, 299
123	FCGRT	-	D11666	Nipocalimab	[4] 46, 49, 53, 61
124	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D00939	Alendronic acid	[7] 19, 41, 46, 50, 271, 274, 299
125	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D00942	Risedronic acid	[9] 46, 50, 66, 93, 95, 96, 107, 113, 274
126	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D01968	Zoledronic acid	[13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
127	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D03234	Risedronic acid	[9] 46, 50, 66, 93, 95, 96, 107, 113, 274
128	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D06378	Zoledronic acid	[13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
129	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D06379	Zoledronic acid	[13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
130	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D07119	Alendronic acid	[7] 19, 41, 46, 50, 271, 274, 299
131	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D08056	Ibandronate	[3] 46, 49, 274
132	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D08484	Risedronic acid	[9] 46, 50, 66, 93, 95, 96, 107, 113, 274
133	FDPS	[4] Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection	D08689	Zoledronic acid	[13] 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
134	POLA2	[1] DNA replication	D03546	Clofarabine	[6] 46, 49, 60, 96, 234, 326
135	MTOR	[51] EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy	D00753	Sirolimus	[41] 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
136	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
137	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
138	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
139	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
140	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
141	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
142	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
143	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
144	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
145	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
146	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
147	GABRA1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
148	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
149	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
150	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
151	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
152	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
153	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
154	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
155	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
156	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
157	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
158	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
159	GABRA2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
160	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
161	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
162	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
163	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
164	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
165	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
166	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
167	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
168	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
169	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
170	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
171	GABRA3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
172	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
173	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
174	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
175	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
176	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
177	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
178	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
179	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
180	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
181	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
182	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
183	GABRA4	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
184	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
185	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
186	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
187	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
188	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
189	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
190	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
191	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
192	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
193	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
194	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
195	GABRA5	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
196	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
197	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
198	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
199	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
200	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
201	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
202	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
203	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
204	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
205	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
206	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
207	GABRA6	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
208	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
209	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
210	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
211	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
212	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
213	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
214	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
215	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
216	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
217	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
218	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
219	GABRB1	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
220	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
221	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
222	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
223	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
224	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
225	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
226	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
227	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
228	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
229	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
230	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
231	GABRB2	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
232	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
233	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
234	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
235	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
236	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
237	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
238	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
239	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
240	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
241	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
242	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
243	GABRB3	[6] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
244	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
245	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
246	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
247	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
248	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
249	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
250	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
251	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
252	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
253	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
254	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
255	GABRD	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
256	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
257	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
258	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
259	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
260	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
261	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
262	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
263	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
264	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
265	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
266	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
267	GABRE	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
268	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
269	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
270	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
271	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
272	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
273	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
274	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
275	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
276	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
277	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
278	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
279	GABRG1	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
280	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
281	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
282	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
283	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
284	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
285	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
286	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
287	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
288	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
289	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
290	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
291	GABRG2	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
292	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
293	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
294	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
295	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
296	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
297	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
298	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
299	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
300	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
301	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
302	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
303	GABRG3	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
304	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
305	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
306	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
307	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
308	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
309	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
310	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
311	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
312	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
313	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
314	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
315	GABRP	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
316	ABL1	[11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis	D01441	Imatinib	[12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
317	ABL1	[11] ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis	D08066	Imatinib	[12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
318	GHR	[5] Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action	D02691	Somatotropin	[23] 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299
319	GNRHR	[2] Neuroactive ligand-receptor interaction, GnRH signaling pathway	D01685	Cetrorelix	[1] 46
320	GNRHR	[2] Neuroactive ligand-receptor interaction, GnRH signaling pathway	D07665	Cetrorelix	[1] 46
321	GRIN1	[18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism	D00848	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
322	GRIN1	[18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism	D03742	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
323	GRIN1	[18] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism	D03744	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
324	GRIN2A	[19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus	D00848	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
325	GRIN2A	[19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus	D03742	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
326	GRIN2A	[19] Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus	D03744	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
327	GRIN2B	[19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus	D00848	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
328	GRIN2B	[19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus	D03742	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
329	GRIN2B	[19] Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus	D03744	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
330	GRIN2C	[15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism	D00848	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
331	GRIN2C	[15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism	D03742	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
332	GRIN2C	[15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism	D03744	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
333	GRIN2D	[15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism	D00848	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
334	GRIN2D	[15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism	D03742	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
335	GRIN2D	[15] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism	D03744	Dextromethorphan	[11] 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
336	NR3C1	[1] Neuroactive ligand-receptor interaction	D00088	Hydrocortisone	[9] 46, 53, 75, 78, 81, 83, 97, 98, 299
337	NR3C1	[1] Neuroactive ligand-receptor interaction	D00244	Betamethasone	[5] 46, 83, 90, 96, 235
338	NR3C1	[1] Neuroactive ligand-receptor interaction	D00292	Dexamethasone	[20] 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
339	NR3C1	[1] Neuroactive ligand-receptor interaction	D00385	Triamcinolone	[9] 46, 56, 70, 90, 96, 107, 162, 226, 298
340	NR3C1	[1] Neuroactive ligand-receptor interaction	D00407	Methylprednisolone	[31] 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
341	NR3C1	[1] Neuroactive ligand-receptor interaction	D00472	Prednisolone	[29] 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
342	NR3C1	[1] Neuroactive ligand-receptor interaction	D00473	Prednisone	[34] 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
343	NR3C1	[1] Neuroactive ligand-receptor interaction	D00751	Methylprednisolone	[31] 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
344	NR3C1	[1] Neuroactive ligand-receptor interaction	D00972	Betamethasone	[5] 46, 83, 90, 96, 235
345	NR3C1	[1] Neuroactive ligand-receptor interaction	D00975	Dexamethasone	[20] 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
346	NR3C1	[1] Neuroactive ligand-receptor interaction	D00979	Methylprednisolone	[31] 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
347	NR3C1	[1] Neuroactive ligand-receptor interaction	D00980	Prednisolone	[29] 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
348	NR3C1	[1] Neuroactive ligand-receptor interaction	D00981	Prednisolone	[29] 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
349	NR3C1	[1] Neuroactive ligand-receptor interaction	D00982	Prednisolone	[29] 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
350	NR3C1	[1] Neuroactive ligand-receptor interaction	D00983	Triamcinolone	[9] 46, 56, 70, 90, 96, 107, 162, 226, 298
351	NR3C1	[1] Neuroactive ligand-receptor interaction	D00984	Triamcinolone	[9] 46, 56, 70, 90, 96, 107, 162, 226, 298
352	NR3C1	[1] Neuroactive ligand-receptor interaction	D00985	Triamcinolone	[9] 46, 56, 70, 90, 96, 107, 162, 226, 298
353	NR3C1	[1] Neuroactive ligand-receptor interaction	D01239	Prednisolone	[29] 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
354	NR3C1	[1] Neuroactive ligand-receptor interaction	D01272	Clobetasol propionate	[2] 46, 162
355	NR3C1	[1] Neuroactive ligand-receptor interaction	D01357	Betamethasone	[5] 46, 83, 90, 96, 235
356	NR3C1	[1] Neuroactive ligand-receptor interaction	D01402	Betamethasone	[5] 46, 83, 90, 96, 235
357	NR3C1	[1] Neuroactive ligand-receptor interaction	D01510	Dexamethasone	[20] 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
358	NR3C1	[1] Neuroactive ligand-receptor interaction	D01615	Dexamethasone	[20] 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
359	NR3C1	[1] Neuroactive ligand-receptor interaction	D01632	Dexamethasone	[20] 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
360	NR3C1	[1] Neuroactive ligand-receptor interaction	D01637	Betamethasone	[5] 46, 83, 90, 96, 235
361	NR3C1	[1] Neuroactive ligand-receptor interaction	D01948	Dexamethasone	[20] 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
362	NR3C1	[1] Neuroactive ligand-receptor interaction	D01998	Prednisolone	[29] 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
363	NR3C1	[1] Neuroactive ligand-receptor interaction	D02032	Betamethasone	[5] 46, 83, 90, 96, 235
364	NR3C1	[1] Neuroactive ligand-receptor interaction	D02156	Prednisolone	[29] 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
365	NR3C1	[1] Neuroactive ligand-receptor interaction	D02174	Dexamethasone	[20] 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
366	NR3C1	[1] Neuroactive ligand-receptor interaction	D02286	Betamethasone	[5] 46, 83, 90, 96, 235
367	NR3C1	[1] Neuroactive ligand-receptor interaction	D02591	Dexamethasone	[20] 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
368	NR3C1	[1] Neuroactive ligand-receptor interaction	D02592	Dexamethasone	[20] 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
369	NR3C1	[1] Neuroactive ligand-receptor interaction	D03301	Prednisolone	[29] 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
370	NR3C1	[1] Neuroactive ligand-receptor interaction	D05000	Methylprednisolone	[31] 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
371	NR3C1	[1] Neuroactive ligand-receptor interaction	D05001	Methylprednisolone	[31] 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
372	NR3C1	[1] Neuroactive ligand-receptor interaction	D05002	Methylprednisolone	[31] 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
373	NR3C1	[1] Neuroactive ligand-receptor interaction	D06216	Triamcinolone	[9] 46, 56, 70, 90, 96, 107, 162, 226, 298
374	NR3C1	[1] Neuroactive ligand-receptor interaction	D07715	Clobetasol propionate	[2] 46, 162
375	NR3C1	[1] Neuroactive ligand-receptor interaction	D07715	Clobetasol	[3] 46, 51, 162
376	NR3C1	[1] Neuroactive ligand-receptor interaction	D08416	Prednisone acetate	[4] 46, 49, 162, 224
377	HMGCR	[4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion	D00359	Lovastatin	[11] 6, 34, 46, 79, 156, 160, 195, 206, 263, 280, 310
378	HMGCR	[4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion	D00434	Simvastatin	[21] 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
379	HMGCR	[4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion	D00887	Atorvastatin	[18] 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
380	HMGCR	[4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion	D00893	Pravastatin	[9] 13, 46, 49, 67, 79, 96, 164, 265, 333
381	HMGCR	[4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion	D01915	Rosuvastatin	[11] 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
382	HMGCR	[4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion	D07474	Atorvastatin	[18] 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
383	HMGCR	[4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion	D08410	Pravastatin	[9] 13, 46, 49, 67, 79, 96, 164, 265, 333
384	HMGCR	[4] Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion	D08492	Rosuvastatin	[11] 6, 18, 46, 49, 51, 56, 79, 96, 97, 271, 299
385	HRH1	[3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels	D00364	Loratadine	[4] 13, 46, 89, 98
386	HRH1	[3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels	D00671	Fexofenadine	[2] 13, 46
387	HRH1	[3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels	D07407	Rupatadine	[1] 46
388	HRH1	[3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels	D07958	Fexofenadine	[2] 13, 46
389	HRH2	[3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion	D00318	Famotidine	[7] 6, 46, 61, 86, 98, 107, 300
390	IFNAR1	[18] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer	D11082	Anifrolumab	[2] 46, 49
391	IFNAR2	[17] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer	D11082	Anifrolumab	[2] 46, 49
392	IFNG	[32] Proteasome, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Fluid shear stress and atherosclerosis	D04242	Fontolizumab	[1] 46
393	TUBB8	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00491	Paclitaxel	[2] 46, 85
394	TUBB8	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00570	Colchicine	[7] 2, 42, 46, 56, 93, 210, 266
395	TUBB8	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D05333	Paclitaxel	[2] 46, 85
396	TUBB2B	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00491	Paclitaxel	[2] 46, 85
397	TUBB2B	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00570	Colchicine	[7] 2, 42, 46, 56, 93, 210, 266
398	TUBB2B	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D05333	Paclitaxel	[2] 46, 85
399	IL1A	[21] MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis	D01583	Pirfenidone	[11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
400	IL1B	[44] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D01583	Pirfenidone	[11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
401	IL1B	[44] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D09315	Canakinumab	[10] 46, 56, 84, 106, 107, 108, 113, 266, 267, 269
402	IL1R1	[13] MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis	D02934	Anakinra	[19] 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
403	IL4	[16] Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Leishmaniasis, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection	D03117	Binetrakin	[1] 46
404	IL6	[51] EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis	D01583	Pirfenidone	[11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
405	IL6	[51] EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis	D10080	Sirukumab	[2] 41, 46
406	IL6R	[12] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer	D02596	Tocilizumab	[21] 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
407	IL6R	[12] EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer	D10161	Sarilumab	[5] 41, 46, 84, 107, 271
408	IL10	[22] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection	D01583	Pirfenidone	[11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
409	IL12A	[25] Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis	D09214	Ustekinumab	[17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
410	IL12B	[25] Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis	D09214	Ustekinumab	[17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
411	IL17A	[6] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis	D09967	Secukinumab	[8] 13, 37, 41, 46, 107, 160, 269, 271
412	IL17A	[6] Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis	D11550	Bimekizumab	[3] 46, 97, 271
413	IMPDH1	[3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways	D01392	Mizoribine	[8] 46, 49, 51, 53, 66, 94, 222, 224
414	IMPDH2	[3] Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways	D01392	Mizoribine	[8] 46, 49, 51, 53, 66, 94, 222, 224
415	ITGA4	[14] PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy	D06886	Natalizumab	[6] 13, 15, 25, 46, 63, 96
416	AR	[4] Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer	D03338	Calusterone	[3] 2, 46, 71
417	ITGAL	[12] Rap1 signaling pathway, Cell adhesion molecules, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis	D03959	Efalizumab	[9] 11, 13, 37, 46, 49, 53, 61, 95, 96
418	JAK1	[27] EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer	D09970	Tofacitinib	[15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
419	JAK1	[27] EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer	D10308	Baricitinib	[13] 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
420	JAK1	[27] EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer	D10653	Peficitinib	[1] 46
421	JAK1	[27] EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer	D10871	Filgotinib	[6] 46, 53, 96, 97, 222, 271
422	JAK1	[27] EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer	D10944	Itacitinib	[5] 46, 51, 60, 97, 228
423	JAK1	[27] EGFR tyrosine kinase inhibitor resistance, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Viral carcinogenesis, Pancreatic cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer	D10994	Upadacitinib	[8] 40, 41, 46, 49, 96, 97, 107, 271
424	JAK2	[24] EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D09970	Tofacitinib	[15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
425	JAK2	[24] EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D10308	Baricitinib	[13] 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325
426	JAK2	[24] EGFR tyrosine kinase inhibitor resistance, Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Cholinergic synapse, Prolactin signaling pathway, Adipocytokine signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Growth hormone synthesis, secretion and action, Leishmaniasis, Toxoplasmosis, Tuberculosis, Hepatitis B, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, Chemical carcinogenesis - receptor activation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D10653	Peficitinib	[1] 46
427	JAK3	[15] Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency	D09970	Tofacitinib	[15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
428	JAK3	[15] Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency	D10653	Peficitinib	[1] 46
429	KIT	[11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer	D01441	Imatinib	[12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
430	KIT	[11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer	D08066	Imatinib	[12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
431	KIT	[11] MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer	D10229	Masitinib	[6] 2, 5, 6, 13, 46, 96
432	LTA	[7] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection	D00742	Etanercept	[17] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
433	LTA	[7] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection	D10187	Pateclizumab	[1] 46
434	LTB	[3] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis	D08866	Baminercept	[4] 13, 46, 53, 97
435	MC2R	[5] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome	D00146	Corticotropin	[15] 2, 13, 14, 46, 49, 50, 66, 75, 78, 81, 84, 145, 193, 205, 222
436	MMP13	[3] IL-17 signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action	D08859	Apratastat	[1] 46
437	ACHE	[2] Glycerophospholipid metabolism, Cholinergic synapse	D00670	Donepezil	[9] 5, 6, 13, 46, 78, 124, 127, 156, 206
438	ACHE	[2] Glycerophospholipid metabolism, Cholinergic synapse	D02068	Tacrine	[3] 46, 271, 299
439	ACHE	[2] Glycerophospholipid metabolism, Cholinergic synapse	D07869	Donepezil	[9] 5, 6, 13, 46, 78, 124, 127, 156, 206
440	ACHE	[2] Glycerophospholipid metabolism, Cholinergic synapse	D08555	Tacrine	[3] 46, 271, 299
441	MTNR1A	[2] Neuroactive ligand-receptor interaction, Circadian entrainment	D02689	Ramelteon	[3] 6, 8, 46
442	MTNR1A	[2] Neuroactive ligand-receptor interaction, Circadian entrainment	D08170	Melatonin	[12] 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
443	MTNR1B	[2] Neuroactive ligand-receptor interaction, Circadian entrainment	D02689	Ramelteon	[3] 6, 8, 46
444	MTNR1B	[2] Neuroactive ligand-receptor interaction, Circadian entrainment	D08170	Melatonin	[12] 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
445	SERPINC1	[1] Complement and coagulation cascades	D03674	Enoxaparin	[1] 46
446	SERPINC1	[1] Complement and coagulation cascades	D07510	Enoxaparin	[1] 46
447	ATP1A1	[18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption	D00298	Digoxin	[3] 8, 46, 210
448	ATP1A2	[18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption	D00298	Digoxin	[3] 8, 46, 210
449	ATP1A3	[18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption	D00298	Digoxin	[3] 8, 46, 210
450	NFKB1	[76] Antifolate resistance, MAPK signaling pathway, Ras signaling pathway, cAMP signaling pathway, Chemokine signaling pathway, NF-kappa B signaling pathway, HIF-1 signaling pathway, Sphingolipid signaling pathway, PI3K-Akt signaling pathway, Apoptosis, Longevity regulating pathway, Cellular senescence, Osteoclast differentiation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Prolactin signaling pathway, Adipocytokine signaling pathway, Relaxin signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Epithelial cell signaling in Helicobacter pylori infection, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Viral carcinogenesis, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Pancreatic cancer, Prostate cancer, Chronic myeloid leukemia, Acute myeloid leukemia, Small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Diabetic cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D01146	Iguratimod	[4] 46, 51, 53, 271
451	ATP1A4	[18] cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Insulin secretion, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Endocrine and other factor-regulated calcium reabsorption, Proximal tubule bicarbonate reclamation, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Carbohydrate digestion and absorption, Protein digestion and absorption, Bile secretion, Mineral absorption	D00298	Digoxin	[3] 8, 46, 210
452	NPR1	[10] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Aldosterone synthesis and secretion	D04051	Erythrityl tetranitrate	[1] 46
453	NPR1	[10] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Vascular smooth muscle contraction, Thermogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Aldosterone synthesis and secretion	D05147	Nesiritide	[2] 46, 58
454	NPR2	[5] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Vascular smooth muscle contraction, Oxytocin signaling pathway	D04051	Erythrityl tetranitrate	[1] 46
455	ATP4A	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D00455	Omeprazole	[16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
456	ATP4A	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D01207	Omeprazole	[16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
457	ATP4A	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D01984	Esomeprazole	[8] 13, 46, 86, 98, 107, 113, 298, 299
458	ATP4A	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D04056	Esomeprazole	[8] 13, 46, 86, 98, 107, 113, 298, 299
459	ATP4A	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D05259	Omeprazole	[16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
460	ATP4A	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D05261	Omeprazole	[16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
461	ATP4A	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D07917	Esomeprazole	[8] 13, 46, 86, 98, 107, 113, 298, 299
462	ATP4A	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D09339	Esomeprazole	[8] 13, 46, 86, 98, 107, 113, 298, 299
463	ATP4B	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D00455	Omeprazole	[16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
464	ATP4B	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D01207	Omeprazole	[16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
465	ATP4B	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D01984	Esomeprazole	[8] 13, 46, 86, 98, 107, 113, 298, 299
466	ATP4B	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D04056	Esomeprazole	[8] 13, 46, 86, 98, 107, 113, 298, 299
467	ATP4B	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D05259	Omeprazole	[16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
468	ATP4B	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D05261	Omeprazole	[16] 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
469	ATP4B	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D07917	Esomeprazole	[8] 13, 46, 86, 98, 107, 113, 298, 299
470	ATP4B	[4] Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion	D09339	Esomeprazole	[8] 13, 46, 86, 98, 107, 113, 298, 299
471	OPRD1	[3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction	D02095	Naltrexone	[13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
472	OPRD1	[3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction	D03783	Oxycodone	[7] 6, 13, 46, 70, 226, 231, 298
473	OPRD1	[3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction	D05113	Naltrexone	[13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
474	OPRD1	[3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction	D05312	Oxycodone	[7] 6, 13, 46, 70, 226, 231, 298
475	OPRD1	[3] cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction	D05462	Oxycodone	[7] 6, 13, 46, 70, 226, 231, 298
476	OPRK1	[1] Neuroactive ligand-receptor interaction	D00836	Buprenorphine	[3] 46, 70, 298
477	OPRK1	[1] Neuroactive ligand-receptor interaction	D02095	Naltrexone	[4] 46, 96, 97, 226
478	OPRK1	[1] Neuroactive ligand-receptor interaction	D03783	Oxycodone	[5] 46, 70, 226, 231, 298
479	OPRK1	[1] Neuroactive ligand-receptor interaction	D05113	Naltrexone	[4] 46, 96, 97, 226
480	OPRK1	[1] Neuroactive ligand-receptor interaction	D05312	Oxycodone	[5] 46, 70, 226, 231, 298
481	OPRK1	[1] Neuroactive ligand-receptor interaction	D05462	Oxycodone	[5] 46, 70, 226, 231, 298
482	OPRK1	[1] Neuroactive ligand-receptor interaction	D07132	Buprenorphine	[3] 46, 70, 298
483	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D00320	Fentanyl	[4] 46, 70, 215, 231
484	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D00836	Buprenorphine	[3] 46, 70, 298
485	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D00842	Morphine	[6] 36, 46, 70, 85, 86, 298
486	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D01355	Tramadol	[5] 46, 70, 78, 226, 271
487	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D01399	Fentanyl	[4] 46, 70, 215, 231
488	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D02095	Naltrexone	[13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
489	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D02271	Morphine	[6] 36, 46, 70, 85, 86, 298
490	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D03783	Oxycodone	[7] 6, 13, 46, 70, 226, 231, 298
491	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D05113	Naltrexone	[13] 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
492	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D05312	Oxycodone	[7] 6, 13, 46, 70, 226, 231, 298
493	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D05462	Oxycodone	[7] 6, 13, 46, 70, 226, 231, 298
494	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D07132	Buprenorphine	[3] 46, 70, 298
495	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D08233	Morphine	[6] 36, 46, 70, 85, 86, 298
496	OPRM1	[3] Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction	D08623	Tramadol	[5] 46, 70, 78, 226, 271
497	IL20	[3] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway	D11756	Fletikumab	[1] 46
498	PDCD1	[3] Cell adhesion molecules, T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer	D10316	Nivolumab	[12] 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159
499	PDE2A	[6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
500	PDE2A	[6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
501	PDE3A	[6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
502	PDE3A	[6] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
503	PDE3B	[11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
504	PDE3B	[11] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
505	PDE4A	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D00302	Dipyridamole	[6] 46, 49, 51, 66, 96, 224
506	PDE4A	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
507	PDE4A	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
508	PDE4A	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D08860	Apremilast	[7] 46, 50, 56, 97, 107, 162, 271
509	PDE4B	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
510	PDE4B	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
511	PDE4B	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D08860	Apremilast	[7] 46, 50, 56, 97, 107, 162, 271
512	PDE4C	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
513	PDE4C	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
514	PDE4C	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D08860	Apremilast	[7] 46, 50, 56, 97, 107, 162, 271
515	PDE4D	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
516	PDE4D	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
517	PDE4D	[5] Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction	D08860	Apremilast	[7] 46, 50, 56, 97, 107, 162, 271
518	PDE1B	[7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
519	PDE1B	[7] Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
520	IL23A	[9] Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis	D09214	Ustekinumab	[17] 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271
521	PDGFRA	[20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer	D01441	Imatinib	[12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
522	PDGFRA	[20] EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer	D08066	Imatinib	[12] 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
523	PGR	[5] Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer	D00182	Norethisterone	[4] 13, 46, 49, 299
524	PGR	[5] Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer	D00951	Medroxyprogesterone acetate	[6] 13, 35, 46, 49, 51, 60
525	PGR	[5] Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer	D00953	Norethisterone	[4] 13, 46, 49, 299
526	PGR	[5] Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer	D08166	Medroxyprogesterone acetate	[6] 13, 35, 46, 49, 51, 60
527	PLG	[4] Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Staphylococcus aureus infection, Influenza A	D01136	Tranexamic acid	[6] 46, 70, 215, 227, 288, 299
528	POLA1	[1] DNA replication	D03546	Clofarabine	[6] 46, 49, 60, 96, 234, 326
529	PPARG	[11] PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis	D00596	Rosiglitazone	[5] 46, 75, 97, 222, 265
530	PPARG	[11] PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis	D00945	Pioglitazone	[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
531	PPARG	[11] PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis	D08378	Pioglitazone	[17] 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
532	PPARG	[11] PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis	D08491	Rosiglitazone	[5] 46, 75, 97, 222, 265
533	PPP3CA	[33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00107	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
534	PPP3CA	[33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00184	Cyclosporine	[44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
535	PPP3CA	[33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D08556	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
536	PPP3CB	[33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00107	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
537	PPP3CB	[33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00184	Cyclosporine	[44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
538	PPP3CB	[33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D08556	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
539	PPP3CC	[33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00107	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
540	PPP3CC	[33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00184	Cyclosporine	[44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
541	PPP3CC	[33] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D08556	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
542	PPP3R1	[32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00107	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
543	PPP3R1	[32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00184	Cyclosporine	[44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
544	PPP3R1	[32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D08556	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
545	PPP3R2	[32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00107	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
546	PPP3R2	[32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D00184	Cyclosporine	[44] 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326
547	PPP3R2	[32] MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis	D08556	Tacrolimus	[34] 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
548	PRKAA1	[20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis	D00944	Metformin	[24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
549	PRKAA1	[20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis	D04966	Metformin	[24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
550	PRKAA2	[20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis	D00944	Metformin	[24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
551	PRKAA2	[20] FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis	D04966	Metformin	[24] 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
552	CACNA2D3	[7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy	D02716	Pregabalin	[5] 13, 36, 46, 70, 298
553	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00267	Chlordiazepoxide	[1] 46
554	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00293	Diazepam	[3] 46, 155, 298
555	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00549	Propofol	[10] 6, 21, 22, 34, 46, 70, 75, 84, 98, 296
556	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00550	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
557	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00693	Chlordiazepoxide	[1] 46
558	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00696	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
559	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D00706	Zolpidem	[3] 5, 6, 46
560	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D01514	Etizolam	[1] 46
561	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D02624	Eszopiclone	[3] 6, 13, 46
562	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D05028	Midazolam	[12] 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
563	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D07784	Delorazepam	[3] 6, 46, 97
564	GABRQ	[5] Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction	D08690	Zolpidem	[3] 5, 6, 46
565	PSMB5	[8] Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases	D03150	Bortezomib	[16] 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331
566	PTAFR	[3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection	D07407	Rupatadine	[1] 46
567	PTGER2	[6] cAMP signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels, Renin secretion, Human cytomegalovirus infection, Pathways in cancer	D00419	Misoprostol	[3] 46, 70, 271
568	PTGER3	[6] Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Human cytomegalovirus infection, Pathways in cancer	D00419	Misoprostol	[3] 46, 70, 271
569	PTGER4	[6] Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels, Renin secretion, Human cytomegalovirus infection, Human papillomavirus infection, Pathways in cancer	D00419	Misoprostol	[3] 46, 70, 271
570	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D00109	Acetylsalicylic acid	[15] 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251
571	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D00118	Naproxen	[4] 13, 46, 107, 271
572	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D00126	Ibuprofen	[7] 13, 46, 65, 107, 113, 271, 299
573	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D00132	Ketoprofen	[1] 46
574	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D00217	Acetaminophen	[18] 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
575	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D00330	Flurbiprofen	[3] 13, 21, 46
576	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D00903	Diclofenac	[5] 13, 34, 46, 78, 271
577	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D00904	Diclofenac	[5] 13, 34, 46, 78, 271
578	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D01122	Ibuprofen	[7] 13, 46, 65, 107, 113, 271, 299
579	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D01475	Flurbiprofen	[3] 13, 21, 46
580	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D01545	Aceclofenac	[1] 46
581	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D02290	Flurbiprofen	[3] 13, 21, 46
582	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D04490	Ibuprofen	[7] 13, 46, 65, 107, 113, 271, 299
583	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D06606	Ibuprofen	[7] 13, 46, 65, 107, 113, 271, 299
584	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D07816	Diclofenac	[5] 13, 34, 46, 78, 271
585	PTGS1	[5] Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes	D08149	Loxoprofen	[2] 46, 271
586	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00109	Acetylsalicylic acid	[15] 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251
587	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00118	Naproxen	[4] 13, 46, 107, 271
588	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00126	Ibuprofen	[7] 13, 46, 65, 107, 113, 271, 299
589	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00132	Ketoprofen	[1] 46
590	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00217	Acetaminophen	[18] 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
591	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00315	Etodolac	[1] 46
592	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00330	Flurbiprofen	[3] 13, 21, 46
593	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00567	Celecoxib	[10] 2, 3, 34, 46, 70, 89, 107, 161, 171, 271
594	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00568	Rofecoxib	[1] 46
595	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00903	Diclofenac	[5] 13, 34, 46, 78, 271
596	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00904	Diclofenac	[5] 13, 34, 46, 78, 271
597	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D00969	Meloxicam	[4] 46, 49, 271, 296
598	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D01049	Nimesulide	[1] 46
599	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D01122	Ibuprofen	[7] 13, 46, 65, 107, 113, 271, 299
600	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D01475	Flurbiprofen	[3] 13, 21, 46
601	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D01545	Aceclofenac	[1] 46
602	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D02290	Flurbiprofen	[3] 13, 21, 46
603	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D02709	Valdecoxib	[1] 46
604	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D03710	Etoricoxib	[2] 46, 271
605	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D03714	Lumiracoxib	[1] 46
606	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D03716	Parecoxib	[2] 46, 271
607	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D04490	Ibuprofen	[7] 13, 46, 65, 107, 113, 271, 299
608	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D06606	Ibuprofen	[7] 13, 46, 65, 107, 113, 271, 299
609	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D07816	Diclofenac	[5] 13, 34, 46, 78, 271
610	PTGS2	[22] Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer	D08149	Loxoprofen	[2] 46, 271
611	PTH1R	[3] Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption	D06078	Teriparatide	[7] 46, 65, 68, 70, 71, 235, 274
612	RRM1	[5] Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways	D01907	Fludarabine	[19] 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
613	RRM1	[5] Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways	D03546	Clofarabine	[9] 19, 20, 40, 46, 49, 60, 96, 234, 326
614	RRM1	[5] Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways	D07966	Fludarabine	[19] 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
615	SCN1A	[1] Dopaminergic synapse	D00358	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
616	SCN1A	[1] Dopaminergic synapse	D01287	Levobupivacaine	[1] 46
617	SCN1A	[1] Dopaminergic synapse	D01450	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
618	SCN1A	[1] Dopaminergic synapse	D02086	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
619	SCN1A	[1] Dopaminergic synapse	D04048	Ropivacaine	[2] 46, 70
620	SCN1A	[1] Dopaminergic synapse	D07552	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
621	SCN1A	[1] Dopaminergic synapse	D08116	Levobupivacaine	[1] 46
622	SCN1A	[1] Dopaminergic synapse	D08127	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
623	SCN1A	[1] Dopaminergic synapse	D08490	Ropivacaine	[2] 46, 70
624	SCN2A	[1] Taste transduction	D00358	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
625	SCN2A	[1] Taste transduction	D01287	Levobupivacaine	[1] 46
626	SCN2A	[1] Taste transduction	D01450	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
627	SCN2A	[1] Taste transduction	D02086	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
628	SCN2A	[1] Taste transduction	D04048	Ropivacaine	[2] 46, 70
629	SCN2A	[1] Taste transduction	D07552	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
630	SCN2A	[1] Taste transduction	D08116	Levobupivacaine	[1] 46
631	SCN2A	[1] Taste transduction	D08127	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
632	SCN2A	[1] Taste transduction	D08490	Ropivacaine	[2] 46, 70
633	SCN3A	[1] Taste transduction	D00358	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
634	SCN3A	[1] Taste transduction	D01287	Levobupivacaine	[1] 46
635	SCN3A	[1] Taste transduction	D01450	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
636	SCN3A	[1] Taste transduction	D02086	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
637	SCN3A	[1] Taste transduction	D04048	Ropivacaine	[2] 46, 70
638	SCN3A	[1] Taste transduction	D07299	Lacosamide	[2] 46, 149
639	SCN3A	[1] Taste transduction	D07552	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
640	SCN3A	[1] Taste transduction	D08116	Levobupivacaine	[1] 46
641	SCN3A	[1] Taste transduction	D08127	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
642	SCN3A	[1] Taste transduction	D08490	Ropivacaine	[2] 46, 70
643	SCN5A	[1] Adrenergic signaling in cardiomyocytes	D00358	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
644	SCN5A	[1] Adrenergic signaling in cardiomyocytes	D01287	Levobupivacaine	[1] 46
645	SCN5A	[1] Adrenergic signaling in cardiomyocytes	D01450	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
646	SCN5A	[1] Adrenergic signaling in cardiomyocytes	D02086	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
647	SCN5A	[1] Adrenergic signaling in cardiomyocytes	D04048	Ropivacaine	[2] 46, 70
648	SCN5A	[1] Adrenergic signaling in cardiomyocytes	D07552	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
649	SCN5A	[1] Adrenergic signaling in cardiomyocytes	D08116	Levobupivacaine	[1] 46
650	SCN5A	[1] Adrenergic signaling in cardiomyocytes	D08127	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
651	SCN5A	[1] Adrenergic signaling in cardiomyocytes	D08490	Ropivacaine	[2] 46, 70
652	SCN9A	[1] Taste transduction	D00358	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
653	SCN9A	[1] Taste transduction	D01287	Levobupivacaine	[1] 46
654	SCN9A	[1] Taste transduction	D01450	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
655	SCN9A	[1] Taste transduction	D02086	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
656	SCN9A	[1] Taste transduction	D04048	Ropivacaine	[2] 46, 70
657	SCN9A	[1] Taste transduction	D07299	Lacosamide	[2] 46, 149
658	SCN9A	[1] Taste transduction	D07552	Bupivacaine	[8] 46, 51, 53, 70, 96, 168, 226, 298
659	SCN9A	[1] Taste transduction	D08116	Levobupivacaine	[1] 46
660	SCN9A	[1] Taste transduction	D08127	Lidocaine	[10] 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
661	SCN9A	[1] Taste transduction	D08490	Ropivacaine	[2] 46, 70
662	CCL2	[17] Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Yersinia infection, Chagas disease, Malaria, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Rheumatoid arthritis, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D01583	Pirfenidone	[11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
663	P2RY12	[1] Platelet activation	D09017	Ticagrelor	[2] 46, 85
664	SLC6A2	[1] Synaptic vesicle cycle	D00228	Amoxapine	[1] 46
665	SLC6A2	[1] Synaptic vesicle cycle	D00821	Venlafaxine	[1] 46
666	SLC6A2	[1] Synaptic vesicle cycle	D08222	Milnacipran	[2] 46, 49
667	SLC6A2	[1] Synaptic vesicle cycle	D08670	Venlafaxine	[1] 46
668	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D00228	Amoxapine	[1] 46
669	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D00821	Venlafaxine	[3] 6, 13, 46
670	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D00822	Citalopram	[7] 6, 8, 13, 18, 46, 98, 127
671	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D02260	Paroxetine	[4] 6, 13, 46, 85
672	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D02362	Paroxetine	[4] 6, 13, 46, 85
673	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D05374	Paroxetine	[4] 6, 13, 46, 85
674	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D05375	Paroxetine	[4] 6, 13, 46, 85
675	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D07704	Citalopram	[7] 6, 8, 13, 18, 46, 98, 127
676	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D08222	Milnacipran	[2] 46, 49
677	SLC6A4	[2] Synaptic vesicle cycle, Serotonergic synapse	D08670	Venlafaxine	[3] 6, 13, 46
678	SYK	[17] NF-kappa B signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Platelet activation, Neutrophil extracellular trap formation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Tuberculosis, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Viral carcinogenesis	D09347	Fostamatinib	[4] 46, 49, 61, 66
679	ADAM17	[4] Notch signaling pathway, Alzheimer disease, Epithelial cell signaling in Helicobacter pylori infection, Coronavirus disease - COVID-19	D08859	Apratastat	[1] 46
680	BTK	[7] NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency	D10893	Acalabrutinib	[2] 46, 61
681	BTK	[7] NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency	D11478	Branebrutinib	[3] 46, 49, 53
682	TNF	[67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D00742	Etanercept	[17] 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285, 298
683	TNF	[67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D01583	Pirfenidone	[11] 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
684	TNF	[67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D02597	Adalimumab	[18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271
685	TNF	[67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D02598	Infliximab	[27] 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271
686	TNF	[67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D03441	Certolizumab pegol	[8] 37, 46, 49, 96, 97, 107, 226, 271
687	TNF	[67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D04358	Golimumab	[8] 46, 56, 84, 96, 97, 107, 270, 271
688	TNF	[67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D05393	Pegsunercept	[1] 46
689	TNF	[67] Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis	D09944	Ozoralizumab	[1] 46
690	TUBB2A	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00491	Paclitaxel	[2] 46, 85
691	TUBB2A	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00570	Colchicine	[7] 2, 42, 46, 56, 93, 210, 266
692	TUBB2A	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D05333	Paclitaxel	[2] 46, 85
693	TYK2	[16] Necroptosis, Osteoclast differentiation, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19	D09970	Tofacitinib	[15] 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271
694	TYMS	[4] Pyrimidine metabolism, One carbon pool by folate, Metabolic pathways, Antifolate resistance	D01244	Tegafur	[1] 46
695	VDR	[5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation	D00129	Calcitriol	[9] 18, 37, 46, 49, 66, 96, 158, 235, 326
696	VDR	[5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation	D00187	Ergocalciferol	[6] 46, 49, 84, 96, 97, 299
697	VDR	[5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation	D00188	Cholecalciferol	[25] 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299
698	VDR	[5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation	D01518	Alfacalcidol	[8] 41, 46, 49, 50, 96, 107, 235, 238
699	VDR	[5] Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation	D07578	Eldecalcitol	[1] 46
700	XDH	[5] Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome	D00224	Allopurinol	[6] 6, 46, 57, 66, 96, 97
701	CACNA2D1	[7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy	D02716	Pregabalin	[5] 13, 36, 46, 70, 298
702	IL1R2	[7] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis	D02934	Anakinra	[19] 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
703	VKORC1	[3] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors	D00564	Warfarin	[13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
704	VKORC1	[3] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors	D01280	Warfarin	[13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
705	VKORC1	[3] Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors	D08682	Warfarin	[13] 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
706	TUBB1	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00491	Paclitaxel	[2] 46, 85
707	TUBB1	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00570	Colchicine	[7] 2, 42, 46, 56, 93, 210, 266
708	TUBB1	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D05333	Paclitaxel	[2] 46, 85
709	TUBB6	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00491	Paclitaxel	[2] 46, 85
710	TUBB6	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D00570	Colchicine	[7] 2, 42, 46, 56, 93, 210, 266
711	TUBB6	[10] Phagosome, Gap junction, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection	D05333	Paclitaxel	[2] 46, 85
712	TNFSF11	[8] Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Prolactin signaling pathway, Parathyroid hormone synthesis, secretion and action, Chemical carcinogenesis - receptor activation, Breast cancer, Rheumatoid arthritis	D03684	Denosumab	[7] 46, 50, 93, 95, 96, 274, 299
713	PDE5A	[3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway	D00302	Dipyridamole	[6] 46, 49, 51, 66, 96, 224
714	PDE5A	[3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway	D00528	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
715	PDE5A	[3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway	D01453	Caffeine	[9] 2, 6, 13, 21, 46, 78, 96, 97, 265
716	PDE5A	[3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway	D02229	Sildenafil	[17] 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
717	PDE5A	[3] Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway	D08514	Sildenafil	[17] 6, 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301
718	TNFSF13	[3] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Rheumatoid arthritis	D09704	Atacicept	[4] 13, 46, 49, 66
719	CD3D	[11] Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency	D08959	Otelixizumab	[1] 46
720	CD3E	[11] Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency	D08959	Otelixizumab	[1] 46
721	CD3G	[10] Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer	D08959	Otelixizumab	[1] 46
722	CACNA2D2	[7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy	D02716	Pregabalin	[5] 13, 36, 46, 70, 298
723	MS4A1	[1] Hematopoietic cell lineage	D02994	Rituximab	[36] 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
724	MS4A1	[1] Hematopoietic cell lineage	D05218	Ocrelizumab	[2] 46, 49
725	MS4A1	[1] Hematopoietic cell lineage	D09031	Veltuzumab	[1] 46
726	MS4A1	[1] Hematopoietic cell lineage	D09314	Ofatumumab	[1] 46
727	CACNA2D4	[7] MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy	D02716	Pregabalin	[5] 13, 36, 46, 70, 298
728	CD80	[10] Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis	D03203	Abatacept	[26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
729	CD80	[10] Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis	D03222	Belatacept	[1] 46
730	CD86	[12] Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis	D03203	Abatacept	[26] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
731	CD86	[12] Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis	D03222	Belatacept	[1] 46
732	PTGES	[2] Arachidonic acid metabolism, Metabolic pathways	D01545	Aceclofenac	[1] 46
733	NR1H4	[1] Bile secretion	D00734	Ursodeoxycholic acid	[11] 46, 67, 84, 93, 94, 95, 96, 97, 234, 296, 299